Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on March 31, 2025
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
GlobeNewswire
·
March 31, 2025
MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they …
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
GlobeNewswire
·
March 31, 2025
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and …
LB Pharmaceuticals Presents New Data from Phase 2 Clinical Trial of LB-102 at the 2025 Annual Congress of the Schizophrenia International Research Society
GlobeNewswire
·
March 31, 2025
Treatment with LB-102 resulted in a positive shift in disease severity as measured by mean change from baseline in Clinical Global Impression of Severity (CGI-S) scores Phase 3 clinical trial of LB-102 in acute schizophrenia expected to initiate in Q4 2025 …
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
GlobeNewswire
·
March 31, 2025
Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or …
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
GlobeNewswire
·
March 31, 2025
DOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while …
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 31, 2025
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, …
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
March 31, 2025
MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell …
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
GlobeNewswire
·
March 31, 2025
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, …
SS Innovations Achieves Significant Milestones in 2024
GlobeNewswire
·
March 31, 2025
The Company’s award winning SSi Mantra surgical robotic system has completed over 3,500 surgeries and is clinically validated to perform more than 100 different types of surgical procedures The Company Continues to Build a Strong Foundation for Future …
Safety Shot Provides Business Update from CEO Jarrett Boon
GlobeNewswire
·
March 31, 2025
SCOTTSDALE, Ariz., March 31, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”), a wellness and dietary supplement company, today provides a business update from CEO Jarrett Boon. To our valued stakeholders, As we …
Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI
GlobeNewswire
·
March 31, 2025
AGOURA HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic,” the “Company,” or “We”), a leader in RNA-based therapeutics, today announced the publication of its latest research paper, titled, “Positive …
TOI Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-based Contracts in Q1
GlobeNewswire
·
March 31, 2025
CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today proudly announced the launch of the Florida …
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
GlobeNewswire
·
March 31, 2025
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer (“NSCLC”) Apollomics to receive …
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 31, 2025
WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced …
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 31, 2025
NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December …
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
GlobeNewswire
·
March 31, 2025
Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, March 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: …
LifeMD to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 31, 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, …
PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF SERIES B CONVERTIBLE PREFERRED STOCK OFFERING
GlobeNewswire
·
March 31, 2025
MINNEAPOLIS, March 31, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging biomedical device company focused on the …
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 31, 2025
-- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 -- -- Raised $10.75 million in private placement financing …
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site
GlobeNewswire
·
March 31, 2025
GARDEN CITY, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …